http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1108721-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69ece09bafee7e0c49d1f7951a3faa2c http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4dac022280ec96f54c694eb427655932 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-12 |
| filingDate | 1999-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_35db1f0f9beaa39f60ad0188cbd27bce http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c491fa7656fa261696144cb2c914089 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_897fa20118110d44a7e3211262f589b7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27f6c2171ff92fcb7800fbaeee2bcd52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_703275c891e7fe359561a2c157db037f |
| publicationDate | 2001-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1108721-A1 |
| titleOfInvention | Thienylalanine derivatives as inhibitors of cell adhesion |
| abstract | The present invention relates to compounds of the formula I,n nin which A, B, X, Y, R 1 , R 2 , R 3 and n have the meanings indicated in the claims. Thencompounds of the formula I are valuable pharmacologically active compounds. Theynare vitronectin receptor antagonists and inhibitors of cell adhesion and are suitablenfor the therapy and prophylaxis of illnesses which are based on the interactionnbetween vitronectin receptors and their ligands in cell-cell or cell-matrix interactionnprocesses or which can be prevented, alleviated or cured by influencing suchninteractions. For example, they can be applied for inhibiting bone resorption bynosteoclasts and thus for treating and preventing osteoporosis, or for inhibitingnundesired angiogenesis or proliferation of cells of the vascular smooth musculature.nThe invention furthermore relates to processes for the preparation of compounds ofnthe formula I, their use, in particular as active ingredients in pharmaceuticals, andnpharmaceutical compositions comprising them. |
| priorityDate | 1999-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 472.